Company intelligence / Profile preview
CancerVax
- Ownership
- Private
- Development stage
- Phase 3
Overview
CancerVax is a pre-clinical biotechnology company developing a universal immunotherapy platform designed to train the immune system to detect, mark, and kill only diseased cells. Their lead program targets Ewing sarcoma; additional programs are in early-stage research with no clinical trial results yet reported. The company collaborates closely with UCLA on foundational research.[3][8][10]
- Therapeutic areas
- Oncology
- Modalities
- Immunotherapy (cancer vaccines)CAR-T cell therapy (universal and personalized)mRNA-based therapeutics (Smart mRNA technology)Nanoparticle delivery systems[1][5][7][9]
- Industry
- Biotech
Drug pipeline
4 assets3 more assets in the full pipeline.
Request access →Partnerships
Beyond the preview
Go deeper on CancerVax.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CancerVax.